ExpreS2ion Biotech Holding AB

EXPRS2

SE0008348262

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:32 2024-05-15 am EDT			5-day change	1st Jan Change
1.44 ^SEK	-0.14%		-2.70%	-31.75%

Apr. 16	ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	CI
Feb. 21	ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	MT

ExpreS2ion Biotech Holding AB Re-Appoints Mazars Set Revisionsbyrå AB as Auditor

May 23, 2019 at 03:44 pm EDT

ExpreS2ion Biotech Holding AB (publ) annual general meeting held on May 23, 2019, approved the re-appointment of MAZARS SET Revisionsbyrå AB as auditor until the end of the Annual General Meeting that will be held next financial year.

Latest news about ExpreS2ion Biotech Holding AB

ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	Apr. 16	CI
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	Feb. 21	MT
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar	Dec. 01	MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
ExpreS2ion Biotech Holding AB Announces Changes to Leadership Team	23-09-27	CI
Expres2ion Biotech Affiliate to Assess Strategic Options for Breast Cancer Project	23-08-17	MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Certain Shares of ExpreS2ion Biotech Holding AB are subject to a Lock-Up Agreement Ending on 14-JUL-2023.	23-07-13	CI
ExpreS2ion Biotech Holding AB(OM:EXPRS2) dropped from S&P Global BMI Index	23-06-19	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
ExpreS2ion Biotech Holding AB Auditor Raises 'Going Concern' Doubt	23-05-01	CI
ExpreS2ion Biotech to Issue New Units to Guarantors Under Rights Issue	23-04-21	MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-09	CI
ExpreS2ion Biotech Names Chief Scientific Officer	23-01-03	MT
ExpreS2ion Biotech Holding AB Appoints Dr. Farshad Guirakhoo as Chief Scientific Officer, Effective January 16, 2023	23-01-03	CI
Evaxion Biotech Teams Up With ExpreS2ion Biotechnologies for Vaccine Candidate Development	22-12-06	MT
ExpreS2ion, Evaxion Team Up to Develop New Cytomegalovirus Vaccine	22-12-06	MT
ExpreS2ion and Evaxion Biotech A/S Initiates Research Collaboration on a Novel Cytomegalovirus Vaccine Candidate	22-12-06	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Expres2ion Biotech Holding AB Announces Durable Antibody Response Reported for the Abncov2 Covid-19 Vaccine Six Months After Vaccination in the Phase Ii Clinical Trial	22-10-17	CI
ExpreS2ion Biotech Holding AB Announces Resignation of Allan Rosetzsky from the Board of Directors	22-10-06	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
Certain Shares of ExpreS2ion Biotech Holding AB are subject to a Lock-Up Agreement Ending on 4-AUG-2022.	22-08-03	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-31	CI

Chart ExpreS2ion Biotech Holding AB

Duration

Period

More charts

Company Profile

ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ExpreS2ion Biotech Holding AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.442 SEK

Average target price

9 SEK

Spread / Average Target

+524.13%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
EXPRES2ION BIOTECH HOLDING AB	-31.75%	6.85M
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-8.48%	33.03B
UCB	+55.32%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-16.39%	15.12B
INCYTE CORPORATION	-8.82%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	8.9B

Biopharmaceuticals